Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Injection shrinks skin tumors before surgery in early trial

NCT ID NCT05858229

First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 20 times

Summary

This study tests an experimental drug called RP1, which is injected directly into skin cancer tumors. The goal is to see if it can safely shrink or eliminate the cancer before surgical removal. Up to 12 adults with resectable cutaneous squamous cell carcinoma will receive the injections, and researchers will check the tumor tissue after surgery for any remaining cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Rochester Dermatologic Surgery

    Victor, New York, 14564, United States

Conditions

Explore the condition pages connected to this study.